Gene therapy rising: Bluebird soars at ASH, Pfizer builds platform
This article was originally published in Scrip
With the potential to cure debilitating diseases, gene therapy has become a darling of the biotechnology industry. The latest evidence: Bluebird Bio's 8 December after-hours stock market rise by 43.2% to $70 per share on data from four transfusion-free beta-thalassemia patients and Pfizer's investment in a gene therapy platform that includes a hemophilia B collaboration with Spark Therapeutics.
You may also be interested in...
As updated Phase I/II results for BioMarin's hemophilia A and Spark's hemophilia B gene therapies were presented on May 22, it was revealed that FDA plans to make hemophilia the first gene therapy indication eligible for accelerated approval based on a surrogate endpoint.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.